Treating CLL With Bruton's Tyrosine Kinase Inhibitors

home / case-based-roundtable-series / treating-cll-with-bruton-s-tyrosine-kinase-inhibitors

This roundtable series reviews the use of Bruton’s tyrosine kinase inhibition as front-line treatment for patients with chronic lymphocytic leukemia discussed in virtual live events.

Part 1: Frontline Treatment Options for CLL by Risk

Part 1: Frontline Treatment Options for CLL by Risk

Targeted Oncology Staff
October 29th 2021

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians the treatment options for patients with chronic lymphocytic leukemia in the front-line setting by risk assessment.

Part 2: BTK Inhibitor Options for Frontline CLL

Part 2: BTK Inhibitor Options for Frontline CLL

Targeted Oncology Staff
November 3rd 2021

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options of BTK inhibitors in patients with chronic lymphocytic leukemia.

Part 3: Considerations for Venetoclax-Based Therapy in Frontline CLL

Part 3: Considerations for Venetoclax-Based Therapy in Frontline CLL

Targeted Oncology Staff
November 5th 2021

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians frontline treatment options in patients with chronic lymphocytic leukemia.

Part 1: BTK Inhibitors for CLL in the Second Line

Part 1: BTK Inhibitors for CLL in the Second Line

Targeted Oncology Staff
November 18th 2021

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL

Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL

Targeted Oncology Staff
November 22nd 2021

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

Part 1: Sandoval Sus Discusses Recommended Treatments for a Patient With CLL

Part 1: Sandoval Sus Discusses Recommended Treatments for a Patient With CLL

Targeted Oncology Staff
December 13th 2021

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

Part 2: Supporting Data for Ibrutinib-Based Regimens in Frontline CLL

Part 2: Supporting Data for Ibrutinib-Based Regimens in Frontline CLL

Targeted Oncology Staff
December 22nd 2021

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline treatment options for patients with chronic lymphocytic leukemia, with questions by Targeted Oncology.

Choosing Between Venetoclax or BTK Inhibitors in Frontline CLL

Choosing Between Venetoclax or BTK Inhibitors in Frontline CLL

Targeted Oncology Staff
February 14th 2022

During a live virtual event, Javier Pinilla-Ibarz, MD, PhD, discussed treatment options for chronic lymphocytic leukemia including ibrutinib, acalabrutinib, and venetoclax with obinutuzumab.